Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Waitlist Available
Sponsor: Melanie Salerno, RN
No Placebo Group
Trial Summary
What is the purpose of this trial?Fecal Incontinence affects an estimated 2-20% of the general population, and up to 50% of the elderly and institutionalized population. Patients with incontinence tend to suffer in silence; they often do not seek help because of embarrassment and stigma. They often become confined to their homes because they are afraid of having an "accident". Although this is not a life-threatening condition, the psychological, emotional, and social impact can be devastating.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Patients with Fecal IncontinenceExperimental Treatment1 Intervention
Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
Find a clinic near you
Research locations nearbySelect from list below to view details:
LifespanProvidence, RI
Loading ...
Who is running the clinical trial?
Melanie Salerno, RNLead Sponsor
LifespanCollaborator